NCT01279018

Persistent Pain After Breast Cancer Treatment With Docetaxel

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,490 (actual)
• Sponsor: Rigshospitalet, Denmark · Academic / Other
• Sex: Female
• Age: 18 Years – 80 Years
• Healthy volunteers: —

Summary

Breast cancer treatment is for many patients followed by sequelae, such as persistent pain, sensory disturbances, lymphedema and reduced physical function. These undesired consequences of the treatment are a major clinical problem, with persistent pain affecting 25-60%, sensory disturbances 20-80%, lymphedema 2-86% and reduced physical function 13-28% of patients. Development of persistent pain after breast cancer treatment, involves a complex pathophysiology that involves pre-, intra- and postoperative factors. Several risk factors for the development of persistent pain after breast cancer treatment have been identified; young age, psychosocial factors, surgical procedure and radiation therapy. Neurotoxicity is a well know attribute of many chemotherapeutic agents, such as taxanes. The purpose of this nationwide study is to retrospectively examine a cohort of breast cancer patients treated with docetaxel, to clarify if docetaxel may influence the prevalence and intensity of persistent pain and other sequelae.

Conditions

• Breast Neoplasms
• Pain, Postoperative
• Neuralgia
• Lymphedema

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2011-01-19
• Last updated: 2011-01-19